Edinburgh Cancer Centre Western General

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Lung cancer4 trials

Phase

• Phase 33 trials
• Phase 21 trial

Status

• Active, not recruiting3 trials
• Recruiting1 trial

Lead sponsor

• Janssen Research & Development, LLC4 trials

Running trials

• Recruiting

  A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

  NCT05498428· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

  NCT04988295· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

  NCT04538664· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04487080· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer1 recruiting